Active Not RecruitingNCT06825858
A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration
PHASE1 · 9 planned enrolment
- Countries listed
- 1
- Registry update
- January 8, 2026
